Company in the news: AstraZeneca

The stock market can be a funny place. Less than a year ago shares in AstraZeneca (LSE: AZN) were changing hands for just over £30 per share.

The company was seen as one of the weakest players in the global pharmaceutical industry, facing years of declining sales and profits as some of its blockbuster drugs came off patent and became exposed to competition from cheap generic ones. Yet value is often in the eye of the beholder.

US drug giant Pfizer has had two bids (the latest being tabled at £50 per share) for AstraZeneca rejected, because the management [...]

MoneyWeek magazine

Latest issue:

Magazine cover
Hard cash

What's next for gold and silver?

The UK's best-selling financial magazine. Take a FREE trial today.
Claim 4 FREE Issues
Shale gas 'fracking' promises to transform Britain's energy market. Find out what it is, what it means, and how to invest.

More from MoneyWeek

FREE REPORT:
What you should really do with your money (2014 Edition)


How to buy and sell penny shares

A beginner's guide to investing in gold

How to invest in British fracking